key: cord-0321970-o09sr2co
authors: Yuan, Mengqi; Chen, Xiangyu; Zhu, Yanzhi; Dong, Xiaoqing; Liu, Yan; Qian, Zhaohui; Ye, Lilin; Liu, Pinghuang
title: A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
date: 2022-05-12
journal: bioRxiv
DOI: 10.1101/2022.05.11.491588
sha: 33e5b2cf5bf5744037e9c79e81119654437a09ab
doc_id: 321970
cord_uid: o09sr2co

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants, especially the Omicron variant, have impaired the efficacy of existing vaccines and most therapeutic antibodies, highlighting the need for additional antibody-based tools that can efficiently neutralize emerging SARS-CoV-2 variants. The use of a “single” agent to simultaneously target multiple distinct epitopes on the spike is desirable to overcome the neutralizing escape of SARS-CoV-2 variants. Herein, we generated a human-derived IgG-like bispecific antibody (bsAb), Bi-Nab35B5-47D10, which successfully retained the specificity and simultaneously bound to the two distinct epitopes on RBD and S2. Bi-Nab35B5-47D10 showed improved spike binding breadth among wild-type (WT) SARS-CoV-2, variants of concern (VOCs) and variants being monitored (VBMs) compared with its parental mAbs. Furthermore, pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa (B.1.617.1) and VOCs including Delta (B.1.617.2), Omicron BA.1 and Omicron BA.2. Crucially, Bi-Nab35B5-47D10 substantially improved neutralizing activity against Omicron BA.1 (IC50= 27.3 ng/mL) and Omicron BA.2 (IC50= 121.1 ng/mL) compared with their parental mAbs. Therefore, Bi-Nab35B5-47D10 represents a potential effective countermeasure against SARS-CoV-2 Omicron and other variants of concern. Importance The new highly contagious SARS-CoV-2 Omicron variant caused substantial breakthrough infections and has become the dominant strain in countries across the world. Omicron variants usually bear high mutations in the spike protein and exhibit considerable escape of most potent neutralization monoclonal antibodies and reduced efficacy of current COVID-19 vaccines. The development of neutralizing antibodies with potent efficacy against the Omicron variant is still an urgent priority. Here, we generated a bsAb, Bi-Nab35B5-47D10, that simultaneously targets SARS-CoV-2 RBD and S2 and improved neutralizing potency and breadth against SARS-CoV-2 WT and the tested variants compared with their parental antibodies. Notably, Bi-Nab35B5-47D10 has more potent neutralizing activity against the VOC Omicron pseudotyped virus. Therefore, Bi-Nab35B5-47D10 is a feasible and potentially effective strategy to treat and prevent COVID-19.

specific mAb ( Fig. S1A and B ). Based on 35B5 and 47D10, we designed two molecular 135 topologies of bsAbs: 35B5VL-VH → G4S linker → 47D10VL-VH (Fig. 1A) and 47D10VL-136 VH → G4S linker → 35B5VL-VH (Fig. B) . To prevent possible steric resistance caused 137 by the SARS-CoV-2 spike trimer, the empirical choice of 5X G4S linkers was made. 138

To maintain the antibody Fc-mediated activities, the individual 35B5 and 47D10 ScFvs 139 were then connected using 5X G4S linkers and fused to the IgG1 Fc to generate the 140 IgG-like bsAbs molecule (Fig. 1C) . Two bsAbs, Bi-Nab47D10-35B5 and Bi-Nab35B5-47D10, 141

were produced by using the ExpiCHO TM Expression System and purified by affinity 142

To evaluate the biological activity of Bi-Nab47D10-35B5 and Bi-Nab35B5-47D10, we 144 initially verified whether they were correctly folded soluble proteins by reducing and 145 nonreducing SDS-PAGE ( Fig. 1D and E). As expected, both Bi-Nab47D10-35B5 and Bi-146

Nab35B5-47D10 ran as homogeneous species at the expected molecular weight: monomer 147 90 kD in the reducing SDS-PAGE gel and dimer 180 kD in the nonreducing SDS-148 PAGE gel ( Fig. 1D and E) . The results indicate that eukaryotically expressed bsAbs 149 fold correctly. 150

Next, to validate the simultaneous spike engagement of the two arms of the bsAbs, 152

we performed an indirect ELISA binding assay. The equal concentrations of S1 protein 153 and S2 protein of the WT SARS-CoV-2 strain were used as the coating antigens . Bi-Nab35B5-47D10 showed the best binding ability to the WT SARS-CoV-2 S1, 155 with the lowest concentration for 50% of maximal effect (EC50) values of 4.2 ng/ml 156 ( Fig. 2A and 2E ). Both Bi-Nab35B5-47D10 and Bi-Nab47D10-35B5 display similar affinity to 157 the S2 protein, although a reduced affinity of bsAbs to the S2 protein compared with 158 the parental mAb 47D10 was observed (Fig. 2B) . These findings confirm that Bi-159

Nab47D10-35B5 and Bi-Nab35B5-47D10 can simultaneously bind both the RBD and the S2 160 epitopes, demonstrating that both arms of the bsAbs are functional. Simultaneously, we 161 assessed the potential of bsAbs to block the binding of angiotensin-converting enzyme 162 as previously described [37] . Consistent with the binding results of bsAbs to WT S1, 164 the Bi-Nab35B5-47D10 exhibited a similar potent blocking interaction between RBD and 165 ACE2 as parental 35B5 and is superior to Bi-Nab47D10-35D5 (Fig. 2C) . Furthermore, Bi-166 Nab35B5-47D10 also substantially bound to the mutated S1 proteins of SARS-CoV-2 167

VOCs, which included HV69-70 deletion and N501Y and D614G mutations, and 168 harbored a similar binding capacity to the VOC S1 with parental 35B5 (Fig. 2D) . Indeed, 169

Bi-Nab35B5-47D10 demonstrated activity equal to, or in some cases better than, that of 170 parental mAbs (Fig. 2E) . These results indicate that Bi-Nab35B5-47D10 retains the binding 171 capacity and breadth of its parental mAbs. 172

Next, we further investigated whether bsAbs could recognize different 174 coronavirus S proteins in the native conformation. Human embryonic kidney (HEK) 175

CoV-2 S protein, Alpha variant (B. 47D10, Bi-Nab47D10-35B5, mAb 35B5 or mAb 47D10, respectively, followed by flow 180 cytometry analysis. ACE2 was used as a positive control (Fig. 3A) . Consistent with the 181 previous results that mAb 35B5 is a SARS-CoV-2-specific neutralizing antibody 182 targeting a conserved epitope on RBD, 35B5 easily detected the expression of four 183 different SARS-CoV-2 S proteins on the HEK293T cell surface with no cross-reactivity 184 of the RaTG S protein (Fig. 3B ). Neither two parental mAbs nor two bsAbs showed a 185 binding signal for the SARS-CoV S protein (data not shown). We found that mAb 186 47D10 cross-reacted with RaTG S protein (Fig. 3C) , which expands the minor cross-187 reaction of Bi-Nab35B5-47D10 and Bi-Nab47D10-35B5 to RaTG S protein ( Fig. 3D and E) . 188

The surface spike protein of Alpha variant, Beta variant and Delta variant was readily 189 detected by both Bi-Nab35B5-47D10 and Bi-Nab47D10-35B5 just as parental 35B5 mAb. 190 Notably, both bsAbs significantly increased the affinity of the Delta variant S protein 191 ( Fig. 3D and 3E ). Taken together, Bi-Nab35B5-47D10 can specifically bind to the native S 192 proteins of SARS-CoV-2 VOCs and VBMs (Fig. 3F) . 193

The emergence of SARS-CoV-2 VBMs with various mutations including Alpha 196 (with N501Y in RBD, T716I, S982A and D1118H in S2), Beta (with K417N, E484K, 197 and N501Y in RBD, A701 V in S2), Gamma (with K417T, E484K and N501Y in RBD, 198 T1027I and V1176F in S2), Epsilon (with L452R in RBD), Eta (with E484K in RBD, 199 F888 L in S2), Iota (with S477N and E484K in RBD, A701 V in S2), Mu (with R346K, 200 E484K and N501Y in RBD, D950N in S2) , Zeta (with E484K in RBD, V1176F in S2), 201 1.617.3 (with L452R and E484K in RBD, D950N in S2) and Kappa (with L452R and 202 E484Q in RBD, Q1071H in S2) escape neutralization and threaten efforts to contain 203 the COVID-19 pandemic (Fig. 4A) . 204

The rational design of bsAb is to avoid escape mutants. To initially assess the 205 virus neutralization capacity of the two bsAbs in comparison to their parental mAbs 206 35B5 and 47D10, we performed neutralization assays with pseudovirus. Because the 207 two parental mAbs target the RBD and S2, respectively, we focused on mutations of 208 VBMs that occur in the RBD and S2 regions (Fig. 4B ). Alpha, beta and kappa variants 209 were chosen to represent VBMs because these variants contain most of the VBM 210 mutations (Fig. 4A ). WT SARS-CoV-2, alpha, beta and kappa variants S protein 211 pseudovirus were incubated with 35B5, 47D10, Bi-Nab35B5-47D10 or Bi-Nab47D10-35B5, 212 respectively, and their transduction was measured according to luciferase activities. As 213 expected, Bi-Nab35B5-47D10 neutralized WT SARS-CoV-2 S pseudovirus effectively 214 with half maximum inhibitory concentration (IC50) values of 8.2 ng/ml (Fig. 5A) and 215 displayed substantially improved neutralization breadth among the three VBM variants, 216 especially for alpha and kappa variants ( Fig. 5B-D) . Among the four antibodies, Bi-217

Nab35B5-47D10 and Bi-Nab47D10-35B5 potently neutralized Alpha and Kappa variants and 218 exhibited comparable neutralization potencies with much lower IC50 values than 219 parental mAbs (Fig. 5B, 5D and 5E). Among the three VBM variants, the beta variant 220 exhibited less sensitivity to the 35B5 mAb (Fig. 5C) . Notably, Bi-Nab35B5-47D10 221 increased the neutralization activity against the beta pseudovirus approximately 6-fold, 222

with the lowest IC50 value of 64.5 ng/ml compared with 35B5 ( Fig. 5C and 5E ). 223

Therefore, these results suggest enhanced cross-reactivity of Bi-Nab35B5-47D10, as 224 indicated by the elevated potency against the WT SARS-CoV-2, Alpha, Beta and 225

Kappa variants (Fig. 5E) . variants. Interestingly, although Bi-Nab47D10-35B5 exhibited substantially lower but 243 detectable neutralization (146.1 ng/ml for Delta, 273.7 ng/ml for Omicron BA.1, 519.2 244 ng/ml for Omicron BA.2). In comparison with 35B5, Bi-Nab35B5-47D10 showed 245 substantially higher neutralization titers against Delta, Omicron BA.1and Omicron 246 BA.2 variants than Bi-Nab47D10-35B5 and parental mAbs with IC50 values of 14.3 ng/ml, 247 27.6 ng/ml and 121.1 ng/ml, respectively (Fig. 7D ). This indicates that the molecular 248 topology of bsAbs substantially impacts the neutralizing activity against VOC variants. 249

Notably, the neutralizing activity of Bi-Nab35B5-47D10 against Omicron was largely 250 enhanced when linking the scFv of 35B5 and 47D10, although mAb 47D10 only 251 slightly neutralized Omicron (Fig. 7D) . Collectively, Bi-Nab35B5-47D10 potently 252 neutralized both the Delta and Omicron variants and substantially increased the 253 neutralization activity in comparison with their parental mAbs. November 2021 [45, 46] . It is still urgent to develop highly potent and broadly 260 neutralizing mAbs targeting multiple SARS-CoV-2 variants [9, 47] . In this study, we 261 generated a potent bispecific mAb Bi-Nab35B5-47D10 targeting spike RBD and S2 in two improved the potency to neutralize Omicron VOC in comparison with parental 35B5 285 (Fig. 7) . Therefore, it is rational that Bi-Nab35B10-47D10 will potently be of interest for 286 further clinical development for COVID-19 treatment. 287

Plasmids containing the heavy and light chain genes for the production of the 290 monoclonal antibodies 35B5 and 47D10 were prepared as previously described [53] . The ExpiCHO TM Expression System (Thermo Fisher) was used to produce bsAbs. 298

Briefly, following the manufacturer's max titer protocol, 25 ml (6×10 6 cells/ml) 299

ExpiCHO-S TM cells in a 125 ml flask were transfected with a master mixture containing 300 25 μg bispecific antibody plasmid and 80 μl ExpiFectamine TM CHO reagent diluted in 301 1 ml cold OptiPRO TM SFM complexation medium. The ExpiFectamine TM CHO/DNA 302 complexes were added to the cells immediately or after up to 5 minutes of incubation at room temperature without any loss of performance. The cells were incubated on an 304 orbital shaker at 37°C with a humidified atmosphere of 8% CO2 humidified in air 305 without the need to change or add media. On the day after transfection, 150 μl 306

ExpiCHO TM enhancer and 6 ml ExpiCHO TM feed were added to the flask. A second 307 volume of ExpiCHO TM feed was added to cultured cells on day 5 posttransfection, and 308 the flask was immediately returned to the shaking incubator. Supernatants were 309 harvested at 4000-5000 x g for 30 minutes in a refrigerated centrifuge, and the 310 supernatant was filtered through a 0.22 μm filter on day 12 posttransfection. 311

Briefly, bsAbs were efficiently purified by using Protein A Sepharose affinity 313 chromatography medium (GenScript, L00210-10). The purified antibodies were 314 separated on a 7.5%-12% polyacrylamide gel and revealed with Coomassie blue under 315 reducing or nonreducing conditions. To assure functionality, stability, and batch-to-316 batch consistency, all antibodies were subjected to quality control and biophysical 317 characterization. 318

HEK293T cells producing pseudovirus and HEK293 cells overexpressing 320 recombinant human ACE2 (293/hACE2) were preserved in our laboratory and 321 maintained in Dulbecco's modified Eagle's medium (DMEM, Thermo Fisher) 322 containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin and 323

were incubated at 37℃ with 5% CO2 and 95% humidity. ExpiCHO-S TM cells (Thermo 324 Fisher) were cultured in ExpiCHO TM expression medium in 125 mL shaker flasks in a 325 37°C incubator with ≥ 80% relative humidity and 8% CO2 on an orbital shaker with a 326 50 mm shaking diameter rotating at 95 rpm. For routine maintenance, ExpiCHO-S TM 327 cells were typically passaged every 3 days at a ratio of 1:20 when they were grown to 328 3-5×10 6 cells/mL. The pcDNA3.1-hACE2 plasmid with human codon optimization, 329 plasmids encoding WT SARS-CoV-2 S glycoprotein, SARS-CoV-2 VBM spike 330 protein, SARS-CoV-2 VOC S glycoprotein, RaTG S glycoprotein, lentiviral packaging plasmid psPAX2 and pLenti-GFP lentiviral reporter plasmid were generously gifted by 332

Dr. Zhaohui Qian. 333

To evaluate antibody characterization in vitro, the ELISA method with 335 modifications was used as reported previously [54] . In brief, 50 nanograms (ng) of 336 SARS-CoV-2 S1 protein of the WT strain (Sino Biological, 40591-V08H) or B.1.1.7 337 (Sino Biological, 40591-V08H7) or SARS-CoV-2 S2 (Sino Biological, 40590-V08B) 338 protein or SARS-CoV-2 RBD protein (Sino Biological, 40592-V08B) was coated on 339 ELISA plates in 100 μl per well at 37°C for 2 hours or 4°C overnight. After washing 3 340 times with PBST, blocking buffer with 5% FBS and 0.05% Tween 20 was added to the 341 ELISA plates and incubated for 1 hour at 37°C. Next, 100 mL serially diluted mAbs or 342 bsAbs was added to each well in 100 μl blocking buffer for 1 hour at 37°C. Following 343 washing 3 times, mouse anti-human IgG Fc secondary antibody with HRP (Abcam) 344 was added and incubated at 37°C for 1 h, followed by washing with PBST. The ELISA 345 plates were reacted with 3,30,5,50-tetramethylbenzidine (TMB, Sigma) substrate at 346 25°C for 5 minutes and then stopped by 0.2 M H2SO4 stop buffer. The optical density 347 (OD) at 450 nm was measured using an iMark microplate absorbance reader (BIO-348 RAD). Nonlinear regression was used to calculate the EC50. 349

The ability of antibodies to inhibit the binding of the SARS-CoV-2 RBD to 351 hACE2 was investigated by ELISA. The 96-well ELISA plates were coated with 200 352 ng of hACE2 protein (Sino Biological, 10108-H08H) per well overnight at 4°C, washed 353 with PBST and blocked for 1 hour with blocking buffer as above. Meanwhile, fivefold 354 serial dilutions of mAbs or bispecific antibodies were incubated with 4 ng/mL SARS-355

CoV-2 RBD with mouse IgG FC tag protein (Sino Biological, 40592-V05H) for 1 hour 356 at 25°C. Then, the mixtures were added to ELISA plates and incubated for 1 hour at 357 37°C. After further washing, bound SARS-CoV-2 RBD protein was detected with anti-358 mouse Fc HRP antibody (Abcam) diluted 1:10000 in blocking solution followed by 359 washing with PBST. The ELISA plates were reacted with TMB substrate at 25°C for 5 360 minutes and then stopped by 0.2 M H2SO4 stop buffer and determined at OD 450 nm. 361

The IC 50 was determined by using 4-parameter logistic regression. 362

Generation of SARS-CoV-2 or SARS-CoV-2 VOC-type pseudoviruss was 365 performed as previously described [55] . In brief, pseudoviruses were produced by using 366 PEI to cotransfect 293T cells with psPAX2, pLenti-GFP and plasmids encoding SARS-367

CoV-2 S, SARS-CoV-2 VOCs S, SARS-CoV S, RaTG S or empty vector at a ratio of 368 1:1:1. The media was replaced with fresh media containing 10% fetal bovine serum and 369 Reporter Assay System (Promega), and cells were lysed with 120 μl medium containing 381 50% Steady-Glo and 50% complete cell growth medium at room temperature for 5 382 minutes. The percentage of infection was normalized to those derived from cells 383 infected with SARS-CoV-2 pseudotyped virus in the absence of antibodies. The IC50 384 was determined by using 4-parameter logistic regression. 385

Flow cytometry-based bsAb binding assay.

HEK293T cells 80-90% confluent in 6-well cell culture plates were transfected 387 with 2 μg of plasmids encoding either WT SARS-CoV-2 S or SARS-CoV-2 mutated S 388 protein or SARS-CoV S protein or RaTG S protein using linear polyethylenimine (PEI, 389

Sigma-Aldrich, 408727). A total amount of 2 μg DNA diluted in 1 ml per well of 390 DMEM was mixed with PEI in a 1:2 ratio. The transfection mixture was added to cell 391 culture plates with DMEM in a dropwise manner after 15 minutes of incubation at room 392 temperature. After 4-6 hours of incubation at 37°C under 5% CO2, the medium was 393 changed to fresh complete cell growth medium (DMEM supplemented with 10% FBS 394 and 1% penicillin-streptomycin). Cells were detached by using PBS with 1 mM EDTA 395 40 hours post-transfection and washed with cold PBS containing 2% FBS. After 396 washing, the cells were incubated with bsAbs, monoclonal human anti-SARS-CoV-2 397 RBD antibody 35B5 or monoclonal human anti-SARS-CoV-2 S2 antibody 47D10 (5 398 μg per well) for 1 hour on ice, followed by FITC-conjugated anti-human IgG (1:100) 399 (ZSGB-Bio, ZF-0308) for 1 hour on ice away from light. Cells were acquired by flow 400 cytometry (BD Biosciences) and analyzed using FlowJo. 401

All statistical analyses were performed using GraphPad Prism 9.0 software. In the 403 ELISA, three independent experiments were performed, and the mean values ± SEM 404 and the EC50 values were calculated by using sigmoidal dose-response nonlinear 405 regression. In the ELISA-based inhibition assay and pseudovirus neutralization assay, 406 three or two independent experiments were performed, and the mean values ± SEM and 407

the IC50 values were plotted by fitting a nonlinear four-parameter dose-response curve. 408 

Delta variant (B.1.617.2) sublineages do not 492 show increased neutralization resistance

Serum neutralization of SARS-CoV-2 Omicron 495 sublineages BA.1 and BA.2 in patients receiving monoclonal 496 antibodies. Nat Med, 2022. replication and immune evasion

Striking antibody evasion manifested by the 501

Omicron variant of SARS-CoV-2

Reduced sensitivity of SARS-CoV-2 variant 504

Delta to antibody neutralization

Evidence of escape of SARS-CoV-2 variant

.351 from natural and vaccine-induced sera

Structural basis of a shared antibody 510 response to SARS-CoV-2. Science

Potent SARS-CoV-2 neutralizing antibodies 512 directed against spike N-terminal domain target a single 513

SARS-CoV-2 neutralizing antibody 515 structures inform therapeutic strategies

N-terminal domain antigenic mapping 518 reveals a site of vulnerability for SARS-CoV-2. Cell, 2021

SARS-CoV-2 501Y.V2 escapes neutralization 521 by South African COVID-19 donor plasma

Multiple SARS-CoV-2 variants 524 escape neutralization by vaccine-induced humoral immunity

Longitudinal Tracking of Immune Responses in 527 COVID-19 Convalescents Reveals Absence of Neutralization 528

SARS-CoV-2 Variants of Concern. Front Immunol

Cryo-EM structure of a SARS-CoV-2 532 omicron spike protein ectodomain

Covid-19: Omicron may be more transmissible than 535 other variants and partly resistant to existing vaccines, 536 scientists fear

Increased risk of SARS-CoV-2 538 reinfection associated with emergence of Omicron in South 539

Activity of convalescent and vaccine 541 serum against SARS-CoV-2 Omicron

Antibody evasion properties of SARS-CoV-2 544

Omicron sublineages

Omicron escapes the majority of existing SARS-546

CoV-2 neutralizing antibodies

The Omicron variant is highly resistant 549 against antibody-mediated neutralization: Implications for 550 control of the COVID-19 pandemic

Biparatopic sybodies neutralize SARS-CoV-553 2 variants of concern and mitigate drug resistance

Bispecific IgG neutralizes SARS-CoV-2 556 variants and prevents escape in mice

Engineered Bispecific Antibodies with 559

Exquisite HIV-1-Neutralizing Activity

Bispecific Antibodies for Autoimmune and Inflammatory 562 Diseases: Clinical Progress to Date

A Human Bi-specific Antibody against Zika 565

Virus with High Therapeutic Potential

Bispecific Anti-HIV-1 Antibodies with

Rational development of a human antibody 570 cocktail that deploys multiple functions to confer Pan

CoVs protection

REGN-COV2, a Neutralizing Antibody 573

Outpatients with Covid-19

Factor VIII-Mimetic Function of Humanized 576

Bispecific Antibody in Hemophilia A

A review of bispecific antibodies and 579 antibody constructs in oncology and clinical challenges

Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential 583 for Infection of Human Lung Cells

Structure, Function, and Antigenicity of 586 the SARS-CoV-2 Spike Glycoprotein

Broadly neutralizing anti-S2 antibodies 589 protect against all three human betacoronaviruses that cause 590 severe disease. bioRxiv

Rational design of a trispecific 592 antibody targeting the HIV-1 Env with elevated anti-viral 593 activity

35B5 antibody potently neutralizes SARS-CoV

Omicron by disrupting the N-glycan switch via a conserved Spike 596 epitope

A potent human monoclonal antibody with pan-598 neutralizing activities directly dislocates S trimer of SARS-599

CoV-2 through binding both up and down forms of RBD

Disease severity dictates SARS-CoV-2-specific 602 neutralizing antibody responses in COVID-19

S-Gene Target Failure as a Marker

1.1.7 Among SARS-CoV-2 Isolates in the Greater 606

SARS-CoV-2 variants B.1.351 and P.1 609 escape from neutralizing antibodies

Detection of a SARS-CoV-2 variant of 612 concern in South Africa

Infection and vaccine-induced neutralizing 614 antibody responses to the SARS-CoV-2 B.1.617.1 variant. 615 bioRxiv

mRNA-based COVID-19 vaccine 617 boosters induce neutralizing immunity against SARS-CoV-2

Omicron variant by BNT162b2 vaccinees' sera: a preliminary 621 evaluation

Cross-reacting antibodies enhance 623 dengue virus infection in humans

SARS-CoV-2 Omicron variant: Characteristics and 626 prevention

Structural diversity of the SARS-CoV-2

Omicron spike

Neutralization of SARS-CoV-2 Omicron BA

Bispecific antibodies targeting distinct 632 regions of the spike protein potently neutralize SARS-CoV-2 633 variants of concern

An engineered bispecific human monoclonal 636 antibody against SARS-CoV-2

Comparable neutralisation evasion of SARS-639

CoV-2 omicron subvariants BA.1, BA.2, and BA.3

Omicron sub-lineages BA.4/BA.5 escape BA.1 642 infection elicited neutralizing immunity. medRxiv

Omicron sub-lineage BA.2 may have "substantial 645 growth advantage

Human monoclonal antibodies block the binding 647 of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 648 receptor

Sensitivity of SARS-CoV-2 Variants to 650

Neutralization by Convalescent Sera and a VH3-30 Monoclonal 651

Characterization of spike glycoprotein of SARS-653

CoV-2 on virus entry and its immune cross-reactivity with SARS-654